The Zacks Analyst Blog Highlights MS, VOO, SPY, IVV, SPYM, RSP, EQ and EQWL
MS sees U.S. equities outpacing global markets into 2026, lifting its S&P 500 outlook and spotlighting ETFs poised to benefit.
Zacks·13d ago
More News
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·10mo ago
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium to Present at the Stifel Healthcare Conference
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium Maintains Rights to Itolizumab Following Ono Partnership
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Business Wire·1y ago
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30...
Business Wire·1y ago
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...